Zejing Pharmaceutical (688266.SH): Injection ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (etoposide/cisplatin) has obtained approval for clinical trials.

Zhijun Finance APP News, Zejing Pharmaceutical (688266.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (referred to as the "State Drug Administration"). The clinical trial of the injectable ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (etoposide/cisplatin) for small cell lung cancer has been approved.